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Abstract 
Alpha-1 antitrypsin deficiency (AATD) is the most common hereditary disorder in 
adults. It is associated with an increased risk of developing pulmonary emphysema 
and liver disease. The pulmonary emphysema in AATD is strongly linked to smoking, 
but even a proportion of never smokers develop progressive lung disease. A large 
proportion of individuals affected remain undiagnosed and therefore without access to 
appropriate care and treatment. 
The last international statement on AATD was published by the American Thoracic 
Society and the European Respiratory Society in 2003. Since then there has been a 
continuous development of novel, more accurate and less expensive genetic 
diagnostic methods. Furthermore, new outcome parameters have been developed and 
validated for use in clinical trials and a new series of observational and randomised 
clinical trials have provided more evidence concerning the efficacy and safety of 
augmentation therapy, the only specific treatment available for the pulmonary disease 
associated with AATD. 
As AATD is a rare disease, it is crucial to organise national and international 
registries and collect information prospectively about the natural history of the 
disease. Management of AATD patients must be supervised by national or regional 
expert centres and inequalities in access to therapies across Europe should be 
addressed. 
 
Keywords: Alpha-1 antitrypsin deficiency; COPD; emphysema; diagnosis; treatment; 
augmentation therapy. 
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Introduction 
It has been over 50 years since the first cases of Alpha-1-antitrypsin deficiency 
(AATD) were described (1) and much has been learnt about the condition since then, 
especially in recent years. More than 100 genetic variants have been described and 
those associated with severe plasma deficiency (<11µM or 0.5g/L) are recognised as 
increasing the susceptibility to the development of emphysema even in never 
smokers. The PiZZ homozygous is by far the most prevalent severe deficiency state 
and its additional extra-pulmonary associations with liver cirrhosis, hepatocellular 
cancer, vasculitis and panniculitis are well recognised. Knowledge has progressed by 
the development of local, national and international registries and the mechanisms 
leading to emphysema and cirrhosis and the natural history of the disease are now 
documented in greater detail. The prevalence of AATD in Europe varies from 1/1368 
in Denmark to 1/58319 in Poland following migration patterns (2). 
The complexity of interpreting the genetic variants, their importance, the role of 
patient and family screening as well as disease management requires expertise only 
gained by seeing patients on a regular basis. The role and instigation of augmentation 
therapy and transplantation need careful and multidisciplinary approaches. The 
development of new therapies such as gene silencing strategies, small molecule drugs 
and other anti-inflammatory and anti-proteinase therapies requires the application of 
novel approaches to the design and implementation of clinical trials to overcome 
some of the inherent challenges of conducting clinical research in rare diseases. The 
establishment of patient advocacy organisations and close collaboration with 
clinicians and other health care workers have played and will continue to play, a key 
role in the acquisition of new knowledge and the design and delivery of new clinical 
trials. The views and concerns of patients were undertaken through the European 
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Lung Foundation with National AATD patient organisations. These have both added 
to the development of the current document and are include in the text and 
summarised verbatum in the supplementary material.  
This European Respiratory Society (ERS) statement provides a broad update of the 
“state of the art” knowledge in the study and management of pulmonary disease 
associated with AATD. 
METHOD 
The task force co-chairs (RAS, MM) led all aspects of project management and 
selected the panellists, which included 13 specialists with experience in AATD and/or 
non deficient COPD management, basic and clinical research. The co-chairs and 
panellists discussed the evidence and formulated the statements. All panel members 
were required to disclose any potential conflict of interests. At least one third of the 
panel was free from any such conflicts. 
Task force members compiled a list of issues that they considered important and 
relevant to the diagnosis and management of pulmonary disease in AATD. Our 
literature search used the previous American Thoracic Society/European Respiratory 
Society (ATS/ERS) statement published in 2003 as a starting point (3). The following 
databases were searched up to January 2016 with no language restrictions 
(Supplementary material): MEDLINE, MEDLINE In Process and EMBASE (via 
Ovid), Cochrane Library (Wiley) CENTRAL, CDSR, HTA, EED, and DARE. In 
addition, Conference Proceedings Citation Index via Web of Science and British 
Library’s ZETOC were searched for conference proceedings and abstracts. Refer-
ences of included studies and reviews were checked. The search was confined to 
alpha-1-antitrypsin deficiency of homozygous Z genotype, Null genotype or Null/Z 
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genotype, all abbreviated for this document as AATD. The searches and the 
formulation of statements were supervised by one of the ERS methodologist (DR).  
AATD and lung disease 
The initial 5 cases of AATD reported by Laurell and Eriksson (1) included 3 patients 
with emphysematous lung disease and one young and one old person without obvious 
signs of COPD. Subsequently Eriksson collected a further 33 patients via hospital 
records and hence represented a partially biased cohort (4). Again variability in the 
presence and severity of lung disease was noted, although, in general, the patients had 
early onset of COPD and basal panlobular emphysema. This pattern of disease 
became recognised as the classical clinical phenotype leading to predominant testing 
of younger patients presenting with severe lung disease. However, existing guidelines 
recommend testing all COPD patients irrespective of age and severity (3,5-7). The 
pathophysiology has been thought to reflect the lack of AAT function (a primary 
serum and lung inhibitor of serine proteinases) protecting the lung tissues from 
proteolytic destruction, which is largely neutrophil-dependent. However, although 
smoking amplifies neutrophil recruitment to the lung and is recognised as an 
important risk factor, it fails to explain the diversity of clinical and structural impact 
in both smokers and never smokers with AATD. 
More recently the establishment of AATD registries (8,9) and follow-up data from the 
1972 Swedish birth cohort (10) have highlighted the diversity of impact and type of 
lung disease, including its effect on health status and lung physiology. One of the 
most comprehensive databases is the UK national registry, which now includes in-
depth data and longitudinal follow-up data from over a thousand patients (11). The 
clinical features of these patients have highlighted many facets of the disease that are 
not entirely consistent with a simple AAT/Neutrophil proteinase balance concept. 
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Firstly, there is lack of concordance found between siblings raised with the same 
environmental background. There is no relationship between the FEV1 of such 
siblings even though gas transfer is related (12). This raises two issues, namely, that 
FEV1 is a poor surrogate measure for emphysema for these patients, and that other 
unknown environmental or genetic influences may play a role in determining the 
outcome.  
Secondly, the FEV1 decline reflects a late physiological change in the disease process 
only starting to deviate from normal in the 4th decade, whereas gas transfer is reduced  
much earlier indicating that it may be a more sensitive and specific test of emphysema 
development (13,14). This is supported by the observational monitoring of the 
Swedish birth cohort, where abnormal gas transfer was present in some patients in 
their fourth decade whilst FEV1 remained within normal ranges (15).  
Thirdly, a proportion of never smokers develop emphysema with reduction in FEV1 in 
middle age, whereas some retain normal spirometry into old age (16) and the life 
expectancy of never smokers is close to normal (17). 
Fourthly, physiological assessment confirms a discordance of lung function with 
some patients retaining normal gas transfer even with reduced FEV1 and vice versa 
(18) which reflects (at least in part) the distribution of emphysema (14,19). Indeed, 
the classical basal distribution of emphysema is not always present and a proportion 
of patients display a pattern of emphysema distribution more typical of non-AATD 
deficient COPD (19). These issues have a significant bearing on monitoring patients 
for stability/progression. As indicated above, the earliest change is a decline in gas 
transfer, which may be independent of and faster than FEV1 decline (20). This is 
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particularly evident in very severe disease when gas transfer impairment and 
progression is greatest and average FEV1 decline is least (21,22).  
Fifthly, patients can demonstrate the same clinical features as non-deficient COPD, 
including increased evidence of bronchiectasis, chronic bronchitis, bacterial 
colonisation, frequent exacerbations (but with a greater degree of pulmonary 
inflammation and associated progression), impaired health status and a degree of 
reversibility of airflow obstruction (20,23,24). Therefore, the WHO guidance for 
testing every patient with a diagnosis of COPD or adult onset asthma for AATD 
should be standard (25). 
 
Statement  
The clinical impact of AATD is highly variable. Heterogeneity in lung disease is only 
partly explained by exposure to known risk factors, such as cigarette smoke. 
Lung disease in AATD generally presents at a younger age than “usual” COPD and 
may be misdiagnosed as asthma. 
Although the patients’ clinical phenotype may vary they are more likely to have basal 
emphysema than patients with usual COPD. 
The WHO recommends all patients with a diagnosis of COPD or adult onset asthma 
should be tested for AATD  
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Laboratory diagnosis and hierarchy of testing 
The laboratory diagnosis of AATD has evolved over the last 50 years since the first 
cases of the disorder were reported, based on a low or absent alpha-1 band seen on 
paper electrophoresis (1). We have reviewed the testing hierarchy for the diagnosis of 
AATD. 
The quantitative determination of AAT levels in blood is a crucial first test to identify 
AATD. Original methods, such as radial immunodiffusion and rocket electrophoresis, 
are no longer used in laboratories. Nowadays, the measurement of AAT levels in 
blood is mostly performed by nephelometry or, less commonly, a comparable latex-
enhanced immunoturbidimetric assay (26). 
In the last decade, more reproducible and reliable quantitative techniques based on the 
use of dried blood samples (DBSs) have become more widely available and have 
facilitated centralisation of testing. (27-29).  
AAT is a polymorphic protein with more than 100 genetic variants coded for by two 
alleles in a codominant manner. Many of these reflect point mutations in the gene 
sequence leading to amino acid substitutions, which may affect the electrophoretic 
mobility of the resulting AAT protein. Isoelectric focusing detects these variants, 
which are given letters A-Z depending on their mobility, i.e. faster or slower, 
compared to the most common (normal variant) labeled M labeled as earlier or later 
letters respectively. Other common variants are S and Z with MM, MS, MZ, SS, SZ 
and ZZ protein phenotypes accounting for over 99% of all variants in most of 
population surveys (30). Although phenotyping can only identify protein that is 
present in the blood, it remains a routine test for AATD. The rarer null variants that 
include a variety of gene insertions, deletions and point mutations can result in the 
absence of AAT production, and null heterozygotes can appear to be normal (Mnull) 
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or abnormal (Znull) based on the electrophoretic pattern of protein phenotyping, 
though not consistent with expected family inheritance. Other deficient mutations 
such as MMalton, MWurzburg, MHeerlen also display an M protein electrophoretic 
phenotype. For these reasons, including the necessity for pre- and post- test genetic 
counselling, access to central laboratories and/or AATD expertise is essential (31). 
Standard manual methods have been improved by semi-automation (32) in the last 
decade and result in easier and faster testing, although significant expertise is still 
required for interpretation (33).  
The ranges of serum AAT in the general population, determined according to the 
main genotypes, have been summarised recently (34).  
The optimal threshold level for AAT to discriminate normal PI*MM from other 
genotypes carrying at least one deficient S or Z allele was 24.4µM (1.1g/L) with 
73.4% sensitivity and 88.5% specificity (34). AAT is an acute phase protein and, 
despite average concentrations varying with protein phenotype, there is a high degree 
of overlap, such that plasma level alone is an insufficient parameter to diagnose 
intermediate deficiency due to M heterozygosity with certainty. The acute phase 
response known to influence AAT can be partly recognised by the simultaneous 
quantification of C reactive protein (CRP). However, these issues are overcome by 
protein phenotyping or specifically by genotyping, both of which are independent of 
AAT level. 
Genotyping describes the detection of specific AAT gene mutations, mainly S and Z. 
This approach utilises the principles of polymerase chain reaction (PCR) and can also 
detect rare and null variants such as the MMalton (35-37). However, it can only detect 
known sequence defects and requires specific primers for each of these, some of 
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which (e.g. F and I) are routinely used by some laboratories. The absence of specific 
primers can lead to false results.   
Whole gene sequencing (which is becoming cheaper) will detect stop mutations and 
help elucidate the nature of rarer variants such as E, F, G, I and P without the need for 
specific primers, as well as identify currently unrecognised variants. The optimal 
results of genotyping are obtained when performed in expert laboratories and 
interpreted in conjunction with the protein level and familial relationships by 
experienced AATD clinicians/geneticists. 
Each specialised laboratory has developed its own flow chart for local or national 
AATD detection programmes, starting from sample collection (blood, plasma, DBS) 
(31). The initial step is usually to measure the AAT plasma level, separating severely 
deficient subjects (ZZ, Znull, Nullnull and most SZ) from intermediate levels for M 
heterozygotes (MZ, MS and Mnull) and normal levels (MM). This step is usually 
followed by protein phenotyping, genotyping or whole gene sequencing depending on 
availability and/or the need for more detailed interpretation. With ever reducing costs 
for PCR and gene sequencing, it is likely that genotyping will become the second step 
in the testing algorithm in the future. 
Figure 1 shows a testing algorithm with initial quantitation of the AAT level in blood 
together with a measure of CRP to determine whether the AAT level could be higher 
than usual due to a possible acute phase response. Thereafter protein phenotyping by 
isoelectric focussing or genotyping where specific primers for known mutations are 
available, will identify the most common variants. Whole exon sequencing can be 
undertaken especially if null variants are expected. The role of intron sequencing is 
currently uncertain. 
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Since AATD is hereditary, family testing should be conducted after identification of 
an index case. Parents of an index case are most commonly PiMZ heterozygotes but 
may be informative if available for testing when a null gene is suspected. In reference 
centers siblings are offered testing as well, because with MZ parents there is a 1 in 2 
likelihood of being heterozygote and a 1 in 4 chance of being PiZZ. Identified PiZZ 
siblings are offered follow up as for the initial (index) case. PiMZ siblings should be 
advised against smoking and may be offered testing for their partner as the PiMZ 
protein phenotype is relatively common (1-3% prevalence) and hence the risk of 
subsequent PiZZ children who, by this strategy, will be identified and can be 
monitored during maturation and into adulthood. For the same reason, checking the 
index patient’s partner may detect any deficiency allele and, where present, the 
children would also have a 1 in 2 likelihood of having severe deficiency. Early 
detection of the deficiency in these children is considered best practice, providing no 
legal barrier exists for testing (Figure 2). More widespread testing (beyond first 
degree relatives) may be conducted in some families depending on family history of 
lung disease or parental results (such as one parent being PiZZ). 
It is imperative that appropriate genetic counselling is provided, both before and after 
genetic testing, and in accordance with national legislation (38). Patients need to be 
made aware of all potential implications of having a genetic test prior to testing in 
order to be able to give informed consent. Therefore, patients should be referred for 
expert genetic testing by their doctor. 
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Statement 
 The quantitative determination of AAT levels in blood is a crucial first test to identify 
AATD. Quantitative deficiency must be supported by qualitative tests to identify the 
genetic mutation(s) causing AATD. 
 
Protein phenotyping by isoelectric focusing identifies variants where AAT is present 
in the sample including the rarer variants F, I and P etc.  
 
Genotyping allows a rapid and precise identification/exclusion of S and Z alleles and 
other variants where specific primers are available. 
 
 Gene sequencing remains necessary for those cases where a null variant or a rare 
pathological variant is suspected.  
 
Testing of relatives of identified patients should be considered after appropriate 
counselling  
Genetic testing should be carried out only after informed consent is given and in 
accordance with the relevant guidelines and legislation.  
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Lung disease progression in AATD 
The proportion of individuals with AATD who develop lung disease is largely 
unknown although cross sectional studies indicate that perhaps 50% of never smokers 
retain spirometric lung function in the normal range in later life (16,17). Nevertheless, 
once established it is generally believed that progression is more rapid than in non-
AATD patients with COPD, especially in smokers. However, smoking cessation can 
“normalise” this progression to that of AATD never smokers (20).  
Conventionally, FEV1 has been used as the major indicator for the presence, 
progression and severity of lung disease.  However, FEV1 is a poor surrogate of 
emphysema, whilst gas transfer is more specific. Although these two measures 
correlate in cohort studies, both have to be measured to a high degree of specification 
and do not provide the same information on the clinical phenotype or the rate of 
progression or stability. Similarly, the progression of emphysema measured by lung 
density in CT continues even when FEV1 is stable (14,18,20,22).  
 
Monitoring the progression of lung disease in alpha-1-antitrypsin deficiency 
Physiology/lung function 
The complexity of interpretation of results obtained by common lung function 
measures such as spirometry and CO gas transfer is illustrated by the discordance 
between these two measures as the disease progresses. Rapid FEV1 decliners can be 
identified even when lung function is initially found to be in the normal range and 
rapid decline of gas transfer can occur even when there is severe airflow obstruction 
and little decline in FEV1. This raises the issue of the need to monitor all patients (at 
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least for a time) to assess treatment options including augmentation therapy where 
available. This careful monitoring would include parameters such as FEV1, DLco (or 
DLco/VA), 6-min walking distance and health-related quality of life parameters.  
 
CT densitometry 
CT densitometry has been established as the most specific and sensitive surrogate 
endpoint for the evaluation of therapeutic benefit of augmentation therapy and 
represents a paradigm imaging biomarker. Validation of the methodology as an 
objective and specific measure of emphysema has been extensive (39-44): cross-
sectional studies have shown a close correlation with pathology, lung function indices 
including FEV1 and gas transfer (45-47), health status (47) and exercise capacity (48). 
Longitudinal observational studies demonstrate that, although the progressive loss of 
lung density correlates with deteriorating lung function and health status as 
emphysema worsens (22,49), CT densitometry is a more sensitive means of detecting 
emphysema progression than these ‘traditional’ clinical measures (13,22,50).  
This novel surrogate outcome measure has facilitated the successful completion of 
several randomised placebo-controlled studies over a compressed time frame and with 
smaller sample sizes (51-53) than were estimated to be required in studies that used 
FEV1 as an endpoint (54). As a consequence of the published evidence, a meeting of 
the Blood Products Advisory Committee of the Food and Drug Administration (FDA) 
(55) concluded in 2009 that it accepted ‘serial lung density measurements by HRCT 
as a clinically meaningful endpoint to assess efficacy of augmentation therapy with 
intravenous AAT on emphysema disease progression’ and its use as a primary 
endpoint in Phase 4 studies. 
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Notwithstanding this progress, the validity of CT densitometry as evidence of 
treatment efficacy is still being questioned because of a lack of coexisting signals in 
conventional surrogate measures, such as lung function or health status. The power 
calculations that have been used historically to design the latest interventional study 
predicted that a study of 130 patients over 3 years would be sufficient to demonstrate 
treatment efficacy if CT densitometry was the outcome (51), whereas the use of FEV1 
as outcome would require at least 550 patients per arm over the same period (54). 
Power calculations based on health status as an outcome have not been performed. 
Our systematic review of the literature (see supplement) assessed 200 manuscripts. 
Table 1 shows the results for annual decline in lung density measured as the 15th 
percentile point (abbreviated as PERC15 or PD15) and expressed as g/L annual 
change of density together with FEV1, DLco and Kco (the latter two corrected for 
haemoglobin concentration). The numbers in the Table are based on placebo-treated 
patients in randomised controlled clinical trials, except for the last two where the data 
were collected in follow-up studies. Clearly, there is high variability in the mean 
values in each of the progression parameters. In the AATD population, only 
repeatability of lung density is reported in the literature (56).  In fact, variation for the 
15th percentile point, corrected for differences of total lung volume between two 
scans is minimal, (intraclass correlation coefficient= 0.96; 95% CI: 0.86–0.99) (56).  
A larger set of information on monitoring of emphysema progression comes from 
non-AATD individuals. In the 2005, ATS/ERS Task Force document relating to 
interpretation for lung function tests (57) indicated the optimal method for expressing 
the short-term variability (measurement noise) is to calculate the coefficient of 
repeatability (CR).  
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Statement 
Annual measurement of lung function including post bronchodilator FEV1 and gas 
transfer provides information about disease progression. 
Lung densitometry, as performed in observational cohort studies and randomised 
clinical trials is the most sensitive measure of emphysema progression 
The correlation between change in lung density and any short-term change in 
measures of pulmonary function is weak. However in the longer term, CT lung 
density decline correlates with reduction in FEV1 and health status. 
The role of CT in the follow up of patients in routine clinical practice requires further 
validation.  
 
The risk of lung disease in heterozygotes 
The risk in individuals with MZ genotype 
The susceptibility of patients with the MZ genotype for developing COPD has been 
explored in a meta-analysis by Hersh et al in 2004 (58). Sixteen studies were case-
control or cross sectional with the binary outcome of COPD or airflow limitation and 
7 cross-sectional studies with FEV1 ( % of the predicted value) as a continuous 
outcome. One study included both outcome measures and was included in both 
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analyses (59). Pooled odds ratio (OR) for COPD in heterozygotes compared with 
normal genotype individuals was significantly increased at 2.31 (95% CI 1.60 to 3.35) 
although large heterogeneity was detected among the studies (58). Cross-sectional 
studies and those adjusting for smoking status showed lower and non-significant risk 
estimates compared with case-control studies and those not adjusting for smoking 
status. In the pooled analysis, there was no difference in mean FEV1 (% predicted) 
between PiMM and PiMZ individuals. A subsequent case control study from Norway 
and a multicentre family-based study from Europe and North America (60) found that 
the PiMZ genotype was associated with lower FEV1/(F)VC ratio and more severe 
emphysema on chest CT scan. However, the number of MZs in the two groups was 
small and the study samples were not population based.  
A family-based genetic association study by Molloy et al. (61) tested for PiMZ COPD 
risk specifically within families that already had an identified PiMZ COPD subject. 
The study compared 99 PiMM and 89 PiMZ non-index subjects recruited from 51 
index PiMZ probands with COPD Gold Stage II-IV. These results indicated 
conclusively that PiMZ individuals who smoke have more airflow obstruction and 
clinical COPD than carefully matched PiMM individuals.  
The risk in individuals with SZ genotype  
The number of PiSZ individuals worldwide is less than PiMZ, however the risk for 
COPD is still not fully elucidated. Dahl et al (62) performed a meta-analysis of the 
risk of COPD in individuals with the PIS allele. Twenty one studies were included 
and there were six case-control and cross-sectional studies. In the pooled analysis 
there were 42 PiSZ individuals of whom 27 had COPD. The summary OR for COPD 
in PiSZ individuals was significantly elevated at 3.26 (95% CI:1.24-8.57) compared 
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with PiMM, however, when a significant outlier was removed from the analysis (63) 
the OR was no longer significantly increased. Seersholm et al (64) in a study of 94 
PiSZ individuals, of whom 66 were non-index cases observed that index PiSZ cases 
had a reduced survival. Data from the Italian and Spanish registries (24,65) found that 
PiSZ subjects were older at diagnosis and had more preserved lung function despite 
higher smoking exposure than PiZZ patients. Similarly, a more recent study (66) 
suggested that PiSZ subjects were less susceptible to cigarette smoke than PiZZ and 
that the pattern of emphysema on CT scan at diagnosis was similar  to that seen in 
patients with usual COPD rather than the predominantly basal distribution of 
panlobular emphysema of PiZZ individuals.  
Taken together, these data suggest increased susceptibility of the SZ phenotype for 
the development of COPD in smokers, but more research is needed, including the 
effect of environmental factors in a similar way to that undertaken for MZ subjects 
(61).  
Rarer mutation heterozygotes (such as FZ, IZ, M Malton and M Null mutations) 
There is a paucity of data for rarer AATD mutations but some studies are emerging 
indicating that the F, I and MMalton mutations confer increased susceptibility to COPD 
when inherited with a Z allele. Although the Null mutations associated with AATD 
are rare, studies have shown that Null homozygotes have more severe lung disease 
than PiZZ or PiSZ individuals (67-70) and MNulls have increased lung 
symptomatology and obstructive lung disease (71).  
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Statement 
Never-smoking PiMZ subjects do not have an increased risk for COPD.  
Smoking PiMZ and PiSZ subjects have an increased risk of COPD compared to 
smoking PiMM subjects.  
The role of other heterozygotes remains unknown due to their rarity and potential 
ascertainment bias from measuring AAT in unusual cases of lung or liver disease. 
 
Role and benefits of screening  
There are different approaches to identify individuals with AATD. The first is 
population-based, in which unselected groups have been tested (screening studies). 
The second is targeted-detection studies where patients with an enhanced suspicion of 
having AATD have been tested including those with early onset (<40 yrs age) COPD, 
basal panlobular emphysema, family history of COPD or AATD and those with 
perinatal jaundice, cirrhosis, vasculitis or panniculitis.  
No randomised, control study determining the efficacy of screening programs for 
AATD has been performed. Most screening studies have been selective and did not 
involve random population samples, but include individuals healthier (blood donors) 
or sicker (hospital outpatients) than the general population. A few population-based 
studies that randomly screened the general population (72,73) or large numbers of 
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new-borns (10,74) provided a less biased and more accurate prevalence estimate of 
specific AATD phenotypes. The new-born studies have also provided valuable insight 
into the natural history of AATD, with unbiased assessments in the risks of liver and 
lung diseases. More specifically, these studies have found that individuals tested, 
often had lung function in the normal range at mean ages of 15 (75) and 30 years, 
respectively (76). Data collected at age 35 years suggest that at least some have 
developed a reduction in gas transfer and lung density (15). This is consistent with the 
retrograde analysis that highlighted the higher sensitivity of these measures to detect 
early changes compared to spirometry (14). The most recent birth cohort information 
at ages 37 to 40 years showed that 2 of the 4 current smokers already had COPD (77) 
Potential benefits of systematic screening include genetic counselling, life-style 
recommendations (smoking prevention or cessation, avoidance of high-risk 
occupations, alcohol intake limitation), and consideration for earlier augmentation 
therapy. The potential harms include psychological effects, social discriminatory 
effects and costs. These effects can be addressed, at least partially, by reassurance as 
never smokers who are non-index cases with AATD have a normal life expectancy 
(17,78).  
The largest population-based study published for AATD was carried out in 200,000 
new-born children in Sweden between 1972 and 1974 leading to the identification of 
127 PIZ individuals and 48 PISZ individuals (10). The major purpose was to reduce 
exposure of the child to parental smoking during childhood and adolescence and to 
prevent active smoking. Neonatal screening reduced the smoking rates for 18-20 years 
old compared to age-matched subjects (79) with 6% being current smokers vs 17% 
(p<0.05) and 88% being never smokers vs 65% (p<0.05), though this failed to affect 
smoking among the parents. Similar results were also found in another neonatal 
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screening study in Oregon, with significantly lower smoking initiation rates in 
subjects who had been diagnosed with AATD than in control subjects (27.3% vs 
56.9%; p=0.02) (75).   
Neonatal screening produced no adverse psychological effects in adolescents 
identified at birth with AATD, though parental distress and adverse effects were 
identified in the mother-child relationship (80) and 20 years later the mothers had 
significantly more anxiety than control mothers (81). These concerns have inhibited 
the re-introduction of neonatal screening in Sweden although a clearer understanding 
of the risks/benefits and natural history of the disease are both helpful and reassuring.  
Statement 
Most screening studies have been biased as they did not involve random population 
samples 
 
Population-based screening studies provide less biased prevalence estimates of 
specific AATD protein and clinical phenotypes as well as valuable insight in the 
natural history of AATD 
 
Neonatal screening has been shown to be effective in reducing the smoking rates for 
18-20 years old compared to age-matched individuals. 
 
Screening may have negative psychological effects on parents and on mother-child 
bonding. However, these negative effects can be addressed by comprehensive genetic 
counselling and care provision at centres of excellence for AATD 
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Augmentation therapy for AATD 
Since augmentation is currently the only specific therapy for AATD, it has been a 
topic of intense debate in the literature and the subject of numerous review and 
opinion articles. In rare diseases such as AATD, the difficulty of recruitment to 
clinical trials, coupled with the lack of sensitivity to change of typical outcome 
measures has challenged the development and delivery of clinical trials. Furthermore, 
there is the unusual situation where augmentation has been advocated (and given) for 
some time on the basis of biochemical effect (namely raising AAT level) (82) and 
hence has become established as treatment in many areas of the world, without the 
level of evidence now expected for respiratory outcomes such as FEV1, quality of life 
and mortality. There have been two previous systematic reviews, one focused on 
randomised controlled trials (RCT) of augmentation (83) and the other which 
considered all controlled study designs of augmentation (including non-randomised 
studies) and presented analyses of FEV1 decline (84). In addition, an individual 
patient data analysis of the CT densitometry data from 2 of the randomised controlled 
trials has been reported (85). The latter two studies were supportive of augmentation 
as a treatment capable of reducing, albeit not eliminating, emphysema progression 
(84,85). The meta-analysis conducted by Gotzsche et al (83) also indicated that CT 
density decline was lower on augmentation therapy than placebo but concluded that 
this did not equate to efficacy. A similar view was also expressed in the more recent 
update by the same authors (86) following publication of the RAPID trial (53). 
In order to obtain all evidence about augmentation and minimise bias we used 
standard systematic review methods as described in the online supplement. There 
have been 8 RCTs of intravenous augmentation, 3 against placebo (51-53,87) and 5 
against another active comparator (88-92), generally a newer brand of augmentation 
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therapy. In addition there have been 6 observational studies reporting a control group 
(8,93-97), largely assessing data from registries, and 11 uncontrolled observational 
studies (82,98-108), focussed on pharmacokinetics, safety or novel outcomes. There 
are also 2 ongoing trials (NCT00242385 and NCT01213043). In the interests of 
brevity, the published placebo controlled RCTs are discussed here in detail, whereas 
other published studies are shown in table 3, which contains a brief summary of study 
characteristics and results. 
The RCTs included a total of 315 patients. The earliest RCT included 58 ex-smoking 
PiZZ patients with mild to moderate emphysema, treated for a minimum of 3 years 
and randomised to an infusion of AAT at 250mg/kg or human albumin every 4 weeks 
(51). FEV1 was the primary outcome; secondary outcomes included Kco, DLco and 
change in lung density measured by CT scan. There was no difference in 
physiological decline, but a strong trend towards reduced decline in CT-measured 
lung density.  
The EXACTLE trial included 77 participants with severe alpha-1 antitrypsin 
deficiency treated using weekly infusions of AAT at 60mg/kg or placebo for 2 years, 
with an optional 6 month extension (52). Primary outcome was progression rate of 
emphysema determined by annual CT lung density at TLC, but this was in part an 
exploratory study, as the optimum method of image analysis was uncertain at the 
time. A strong trend toward reduced density deterioration was seen, consistently with  
the four different analytical methods used. In one of these, conventional statistical 
significance was reached (p=0.049). Secondary outcomes included patient reported 
exacerbation frequency, DLco and quality of life. No trends in these measures were 
seen between active treatment and placebo, although there was a reduction in hospital 
admissions for exacerbations in the active treatment arm.  
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The most recently performed study (RAPID) included 180 patients with emphysema 
secondary to AATD and FEV1 of 35-70% predicted (53). Patients received either 
weekly infusions of AAT at 60mg/kg or placebo for 2 years, with a 2- year open label 
extension for some participants (87). This study was the first to be powered to detect a 
treatment effect on the annual rate of decrease in lung density measured by CT scan; 
secondary outcomes included exacerbation rate, change in FEV1 % of predicted, 
quality of life (QOL) using the St Georges Respiratory Questionnaire (SGRQ) and 
change in DLco.  The CT imaging protocol obtained scans at full inspiration (total 
lung capacity, TLC) and at relaxed expiration (functional residual capacity, FRC). 
Whilst the chosen primary endpoint was a combination of CT lung density (PD15) 
measured at TLC and FRC (which failed to achieve statistical significance), the 
separate imaging series at TLC and FRC were included as secondary outcomes. The 
main finding was a reduced rate of lung density decline, as measured by CT scanning, 
in the treated patients. This treatment effect was statistically significant when 
quantified using CT imaging obtained at full inspiration (TLC), as in previous studies 
(see above). During the open label extension, the patients previously on placebo 
exhibited a change in CT density decline becoming similar to that seen in patients 
treated in the randomised phase. However, as in previous RCTs in this area, no 
significant effect was seen on other outcome measures, such as lung function and 
QOL (87). A supplementary report to the trial has also detailed reduced circulating 
desmosine, indicating an effect of augmentation on body elastin breakdown (109).  
Augmentation is considered safe across the larger number of studies where this is 
reported. Adverse event rates were similar between treated and placebo groups in both 
EXACTLE (52) and RAPID (53) , but were not reported in the earlier RCT (51). 
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The consistency of the trial data with respect to CT density decline, and the fact that 
CT density has been shown in cross-sectional and longitudinal studies to relate well to 
other clinical outcomes, such as mortality and QOL (47,110) indicates that it is a 
clinically relevant measure. Moreover decline in CT density has also been shown to 
relate to mortality (111), indicating that the RCT results with respect to CT density 
decline are consistent with the longer observational work suggesting a mortality 
benefit (8). Survival was also reported in the most recent RCT, (1 death on 
augmentation, 3 on placebo) but the low mortality rate prevented any conclusion.  
 Whilst many of the observational studies imply a benefit of treatment on the rate of 
FEV1 decline, the potential for bias is greater than in a RCT, and the data should be 
interpreted with caution. The effect of augmentation on exacerbations of AATD lung 
disease remains uncertain, with inconsistent effects in those RCTs, which reported 
them (52,53), and reduced rates in one retrospective observational study (97). Longer 
duration trials, with use of symptom diaries, and/or selection for frequent 
exacerbations might help to confirm any treatment effect on clinical symptoms, but 
again such studies would require large sample sizes and the inclusion of a placebo 
control group would likely be considered unethical given the evident benefit on CT 
density decline. 
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Statement 
Several randomised clinical trials in severe AATD have shown intravenous 
augmentation therapy to reduce the progression of emphysema as assessed by CT 
densitometry. 
There is no evidence to support efficacy of AAT augmentation therapy in PiSZ, PiMZ 
or current smokers of any protein phenotype. 
Clinical trials have used fixed doses of AAT determined by body weight. Whether 
individualising dosage based on trough levels for each patient has any benefit requires 
confirmation. 
 
Suggested patient assessment and management steps  
This stepwise approach describes the current practice of how members of the task 
force assess and treat patients with AATD and is intended as a guidance not as a 
general recommendation. 
1. Identify patient with severe AAT deficiency. 
2. Ensure smoking is stopped if the patient was a smoker. 
3. Identify and modify any other potential risk factor/s. 
4. Optimise current COPD therapy. 
5. Assess patient in an expert reference centre.  
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6. Instigate augmentation therapy if indicated.  
7. Continue monitoring.   
 
Lung volume reduction surgery in AATD  
Patients with severe emphysema suffer breathlessness in part due to emphysematous 
hyperinflation. It is well established that targeted resection of these areas, in selected 
patients with COPD, can result in significant improvements in quality of life and 
mortality. The last ATS/ERS statement concluded that bilateral lung volume 
reduction surgery (LVRS) offered short term benefit only and was not recommended 
for AATD related emphysema until more data was available (3). Stoller et al (112) 
reported outcomes from NETT study in 10 AATD patients having bilateral LVRS (5 
with upper lobe predominant emphysema). The authors identified a higher mortality 
than medical treatment and a trend towards reduced magnitude and duration of 
beneficial effect compared to usual COPD. Specifically with respect to unilateral 
LVRS in AATD, Dauriat et al (113) compared outcomes in 17 patients with AATD 
versus 35 individuals with non AATD related COPD, finding improvements in both 
groups in FEV1, dyspnoea score and PaO2 at 3-6 months. There was a loss of effect 
on walking distance, but preserved FEV1 and dyspnoea score at 12 months in the 
AATD group. 
These studies were performed a decade or more ago, since when there have been 
significant advances in patient selection, surgery, and the advent of randomised 
controlled clinical trials utilising devices to achieve medical lung volume reduction 
without the need for surgery; i.e. endobronchial valves (EBV), endobronchial coils, 
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lung sealant, thermal vapour. Patient selection is currently advocated through a multi-
disciplinary team approach comprising physician, surgeon, radiologist and 
interventional bronchoscopist with special interest in LVR. It is recognised that 
patients being considered are, by definition, those with advanced disease and thus at 
higher risk, hence risk/benefit analysis is central to the multidisciplinary team 
assessment. Early outcomes from surgical LVR are now improved likely to reflect 
improved patient selection, MDT approach and the fact that most cases involve 
minimally invasive video assisted thoracoscopic surgery (VATS) and a unilateral 
rather than a bilateral procedure. Whether this has an influence on long term outcomes 
is unknown. However, mortality rate is 3% over 20 years post LVRS (114), with 
benefit in both lower and upper lobe disease and very low mortality from unilateral 
VATS (115).  
The range of treatments in development may allow specific patterns of emphysema to 
be treated. The two best evaluated devices are endobronchial coils and EBV. Coils 
have been evaluated in patients with emphysema and significant improvements have 
been shown in 6 minute walking distance, FEV1 and quality of life. Some patients 
with emphysema associated with AATD have been treated with coils, but no results 
have been provided for this specific subgroup of patients. Studies have shown that 
morbidity is increased and therefore personalised risk/benefit analysis is critical 
(116,117). Endobronchial valves are unidirectional valves placed bronchoscopically 
in the airways supplying the target lobe. In common with LVRS, the success of this 
approach remains optimal patient selection – in the case of EBV the absence of 
collateral ventilation between target and non-target lobe is vital to a successful 
outcome. The most recent RCT demonstrated significant improvements in 6 minute 
walking distance, FEV1 and quality of life at 6 months, and also demonstrated that 
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centres need to be aware of potential morbidity of pneumothorax related to non-target 
lobe expansion and be proactive in performing valve maintenance to a high standard 
(118). The study also included some AATD individuals treated with EBV. However, 
owing the rarity of AATD large studies are not currently available to provide detailed 
assessment of coils, EBV or LVRS in AATD alone. Unlike EBV, coils can be used in 
patients with homogeneous emphysema, irrespective of collateral ventilation, but 
there is no specific data on in AATD. The promising results from EBV therapy have 
meant that specialist LVR units no longer exclude appropriate AATD individuals 
from these therapies, though more research is required..  
 
 
Statement 
 
Data is emerging for a successful outcome in selected patients with AATD from EBV 
placement or surgical volume reduction 
The optimal results of these techniques are obtained when a careful appraisal of risks 
and benefits are performed by a multi-disciplinary team experienced in LVR and 
AATD 
 
Lung Transplantation for emphysema associated to AATD 
Severe AATD related emphysema has accounted for 5.4% of all lung transplants 
performed between 1995-2014 (119). Since the last ATS/ERS statement (3), there 
have been several publications reporting outcomes in many established transplant 
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centres in different countries, but all studies have been retrospective. De Perrot et al 
(120) reported a higher early mortality from sepsis in AATD and lower 10-year 
survival in AATD post transplantation compared to usual non deficient COPD, and, 
similarly, Thabut et al (121) have shown that patients with AATD had less survival 
benefit than patients with non deficient COPD. This may relate to associated excess 
inflammation at times of infection in post-transplant AATD individuals (122,123), 
due to the lack of the normal anti-inflammatory role of AAT (124). However, this 
higher, early mortality in AATD post-transplant has not been comfirmed e.g. Burton 
et al (125) reported no differences in early or late mortality for AATD compared to 
non deficient COPD.  
In terms of survival compared with non transplanted AATD patients, Tanash et al 
(126) observed that transplantation increased survival considerably from 5 to 11 years 
compared to non transplanted AATD patients matched for FEV1, age, sex and 
smoking history. The most common cause of death was pulmonary infection among 
the transplant patients and respiratory failure among the controls. In contrast, a UK 
study (127) also matched transplanted and non-transplanted AATD individuals for 
FEV1, age and sex, but found that AATD patients who underwent lung transplant had 
lower gas transfer and quality of life pre-transplant compared to non-transplant 
patients. Further matching adjusted for quality of life (SGRQ), gas transfer factor and 
pre-transplant rate of lung function decline showed that transplantation did not 
increase post-surgical survival although quality of life was much improved. These 
controversial results underscore that the survival benefit of lung transplant is complex 
to assess and studies that compare matched patients with and without transplant are 
(by nature) biased (128). Consequently, survival benefit remains  unclear and thus the 
main indication for transplantation relates to improvement in quality of life. 
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The evaluation of comorbidities is crucial in the assessment of candidates for lung 
transplantation and, hepatic evaluation is particularly critical in AATD, (129). Some 
centers perform systematic liver biopsy in candidates, although the detection of liver 
disease per se does not preclude lung transplant in these patients. There are 
experiences of combined liver and lung transplantation with satisfactory results.   
 
Statement 
The survival benefit of lung transplant in AATD patients is not clear. 
In general, patients with AATD have improved quality of life following lung 
transplantation. 
Referral timing, rate of decline in lung function, health status and social support differ 
from patient to patient and have an influence on the evaluation for transplant. 
The role of post-transplant augmentation therapy in particular needs to be explored  
 
New lines of research in AATD 
There are several aspects of lung disease in AATD that require further research; the 
main topics identified by the group are: 
Biomarkers of emphysema progression in AATD 
Biomarkers of response to augmentation therapy 
Research on the minimum clinically important difference (MCID) in rate of decline in 
lung density 
Personalised augmentation therapy, with individualised selection of therapeutic 
regimen according to the patient needs 
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Development of genetic and regenerative therapies 
Other types of treatment, such as biochemical inhibitors of neutrophil proteinases. 
Development of specific patient-reported outcomes (PROs) for patients with 
emphysema associated with AATD. 
Efficacy of augmentation therapy after lung transplant in AATD patients 
 
 
Organisation of care: reference centres and registries 
Due to the low prevalence and underdiagnosis, AATD is considered a rare disease. It 
is almost impossible for an individual clinician or a single centre to accumulate 
enough expertise in diagnosis and management of the disease; therefore, the care for 
patients with AATD is best organised in reference centres that can provide the highest 
standard of care and advice to the individuals affected and their families whilst also 
contributing to knowledge accumulation. An optimised format of service provision by 
a reference center in AATD is outlined in Figure 3 although other models may be 
applicable. 
The European Commission also recommends the development of reference centres for 
rare diseases. The establishment of European reference networks (ERNs) for rare 
diseases should therefore serve as research and knowledge centres, updating and 
contributing to the latest scientific findings, treating patients from other Member 
States and ensuring the availability of subsequent treatment facilities where necessary. 
The definition of ERNs should also reflect the need for services and expertise to be 
distributed across the EU. In a document released by the European Commission in 
2006, the criteria for reference centres of rare diseases are clearly specified (130) 
(Table 4) 
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Reference centers must establish a registry of their activity and collect information 
prospectively about the natural history of the patients being monitored. These data can 
be shared at national and international levels and be the foundation of the registries of 
AATD. The development of registries is crucial as the only way for the successful 
accumulation of knowledge about the clinical characteristics, evolution, natural 
history and response to treatment of patients with rare diseases, such as AATD.  
Europe was pioneer in the development of national registries for AATD. As early as 
the 70s Sweden (15) and Denmark (78) initiated their registries, followed by other 
countries such as the Netherlands, Spain, Italy, Germany, Ireland, the UK and more 
recently Switzerland, Latvia, Estonia, Czech Republic, Poland, Austria, Belgium and 
France, among others. However, the low prevalence of the disease stimulated the 
organisation of an international registry, not restricted to Europe, but with 
predominance of European countries, the Alpha One International Registry (A.I.R.) 
that was founded in 1997 (9) following the recommendation from the World Health 
Organisation (WHO) to establish such a registry of AATD (25). AIR has been a 
successful platform for the development of clinical trials with new and existing 
therapies for the disease and has contributed to increase the awareness of the disease 
among healthcare professionals across Europe (131).  
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Statement 
According to the European Council, management of patients with AATD should be 
supervised by reference centres of excellence at national or regional level.  
The systematic collection of data concerning clinical characteristics and natural 
history of patients with AATD in national and international registries will enhance 
knowledge about the evolution of this disease and its optimal management.  
For many AATD individuals, a respiratory service is the first point of diagnosis. The 
operational pathway includes varying assessments and follow up depending on 
personalising the patients’ risk and defining the respiratory phenotype. Links to multi-
disciplinary teams will ensure the best quality of care. 
 
Access to optimal care and augmentation therapy for AATD in Europe 
In Europe, health care policy is largely a devolved matter and decisions related to 
provision of healthcare services, disease management and prescription medicines rest 
with national, regional or local policy makers, health technology assessment (HTA) 
agencies and payers. This results in different standards of care for AATD and 
contributes to geographic inequalities in access to optimal healthcare services, clinical 
expertise and effective therapies. Notably, access to high-cost, rare disease therapies, 
such as augmentation therapy for AATD, can vary significantly across jurisdictions 
(132). Augmentation therapy is fully reimbursed in some countries such as Germany, 
Italy, Spain, Portugal, France and others, but not reimbursed in the majority of 
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Eastern European countries and in some Western European countries such as the UK, 
Ireland, Denmark or Sweden (table 5). 
Increasing efforts are being made by policy makers to ensure that patients with rare 
diseases such as AATD have timely, better and more equitable access to high quality 
care. Examples of these initiatives include the European Council Recommendation on 
an action in the field of rare diseases, that required all EU member states to adopt 
national plans and policies for rare diseases by the end of 2013 (133), the European 
Network of HTA agencies (EUnetHTA) that aims to assist in the development of 
reliable, timely, transparent and transferable information to contribute to HTAs in 
European countries (134), and the European Medicine Agency’s (EMA) adaptive 
pathways pilot for medicine development and data generation which allows for early 
and progressive patient access to a medicine (135).  
In the absence of harmonised legislation that regulates AATD healthcare provision 
and access to augmentation therapy and other specific treatments across Europe, only 
multi-stakeholder collaboration and continuous improvement of the available 
evidence-base for efficacy and cost-effectiveness of AATD therapies is likely to 
achieve greater equity in implementation of best practice. 
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Table 1. Laboratory methodologies used in different central national laboratories across Europe  
for diagnosis of AATD 
 
Country Biological sample First-line method(s) Second-line method(s) Further 
method(s) 
Author, year (Ref.) 
Ireland Serum/plasma AAT level Phenotyping Genotyping; 
sequencing 
McElvaney, 2015 
(136) 
Poland Serum/DBS serum AAT level determination of AAT 
levels on dry blood spot 
samples, phenotyping, 
genotyping 
sequencing Chorostowska-
Wynimko, 2015 
(137) 
Serbia Blood Immunonephelometric assay for 
AAT; genotyping 
 IEF; DNA 
sequencing 
Beletic, 2014 (138) 
France Serum quantification of serum α1-AT 
concentration with possible 
complementary measurement of 
the elastase inhibitory capacity 
of serum 
Phenotyping: genotyping Direct 
sequencing 
Balduyck, 2014 
(139) 
Germany 
 
 
Italy 
 
Spain 
DBS 
 
 
DBS 
 
DBS 
AAT level 
 
 
AAT level; genotyping 
 
AAT level 
AAT level by 
nephelometry; genotyping 
 
Phenotyping 
 
Genotyping 
Phenotyping; 
sequencing 
 
Sequencing 
 
Phenotyping; 
sequencing 
Miravitlles, 2010 
(31) 
U.S. Blood/serum AAT level; genotyping Phenotyping - Bornhorst, 2007 
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 (140) 
Italy DBS AAT level; genotyping 
phenotyping 
Sequencing  Ferrarotti, 2007 
(141) 
Poland  Serum level Phenotyping Gene screening Kaczor, 2007 (142) 
Italy Blood/DBS Serum Level Phenotyping Genotyping; 
sequencing 
Corda, 2006 (143) 
U.S. Blood AAT level; genotyping 
 
Phenotyping  Snyder, 2006 (144) 
U.S Plasma-
serum/DBS 
Concentration  
of AAT protein in 
plasma or serum (immunoassay) 
Phenotype (IEF) Genotype 
(PCR); Function 
test (Inhibition 
of leukocyte 
Elastase) 
Campbell, 2000 
(145) 
 
 
Footnote: AAT: alpha-1 antitrypsin; IEF: isoelectrofocusing; PCR: Polymerase chain reaction; DBS: Dried blood spot 
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Table 2. Annual change in lung density (Perc15 or PD15), FEV1 and gas transfer  in 
placebo-treated patients in RCT’s or studies on the natural course of AATD-
associated emphysema. 
Author, 
year (Ref.) 
Patients 
(n=) 
Follow up 
in months 
Perc15 (PD15) 
value (gr/L) 
FEV1 
(ml/yr) 
DLCO* 
 
DLCO/Va** 
(Kco) 
Dirksen 
1999 (51) 
28 36 −2.57 ± 0.41a −59.1 ± 11.9a −0.16 ± .04 a −0.0162± 0.004a 
Dirksen 
2009 (52) 
35 25 -2.241b 
(-2.90– -1.577) 
-23 mlb  
(-0.043– -0.004) 
-0.343b 
(-0.489– -0.196) 
-0.035b 
(-0.051– -0.020) 
Stolk  
2012 (146) 
110 14 -1.81 ± 0.5a -50±13a -0.23 ± 0.05a NA 
Stolk  
2015 (147) 
51 96 NA -66 ± 60.9c NA -0.0275 ±0.00259c 
Chapman 
2016 (53) 
87 24 -2.19±0.23a -2.3±13.1%d -1.5±19.5%d NA 
Green 2016 
(111) 
76 24 -3.2 ± 0.5  -44.67 ± 8.71 -0.37± 0.04 -0.01± 0.01 
 
NA = not available in the manuscript; * unit is mmol/min/kPa; ** mmol/min/kPa/L;  
a(mean ± SE); b(95% CI); c(mean ± SD); d(annual decline in percent predicted) 
 
 
. 
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Table 3. Studies on augmentation therapy for AATD 
Study design Author, year Intervention Comparator Primary 
outcome 
N Duration 
of Rx 
Effect of treatment Ref. 
RCT v 
placebo 
Dirksen et al, 
1999 
250mg/kg 
augmentation 
4 weekly 
625mg/kg 
albumin 
solution 
FEV1 decline 58 ≥3 years FEV1 decline ns diff 59 v 
79ml/yr (p=0.25); 
Reduced CT decline 2.6 v 
1.5g/l/yr (p=0.07) 
 
(51) 
Dirksen et al, 
2009 
60mg/kg 
Prolastin 
weekly 
2% albumin 
solution 
CT 
densitometry 
77 ≥2 years Reduced CT decline 1.4 v 
2.2g/l/yr (p=0.06) 
 
(52) 
Chapman et 
al, 2015 
60mg/kg 
Zemaira 
weekly 
Lyophilised 
preparation 
CT 
densitometry 
180 ≥2 years Reduced CT decline 1.5 v 
2.2g/l/yr (p=0.03) 
 
(53) 
RCT v active 
comparator 
 
 
 
Stoller et al, 
2002* 
60mg/kg 
Prolastin 
weekly 
60mg/kg 
Respitin 
weekly 
Serum AAT 
level 
28 ≥12 
weeks 
Equivalence for 1e 
outcome, ns diff FEV1, 
DLCO, urinary desmosine 
 
 
(88) 
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RCT v active 
comparator 
Stocks et al, 
2006* 
60mg/kg 
Prolastin 
weekly 
60mg/kg 
Zemaira 
weekly 
 
Serum AAT 
level 
44 ≥10 
weeks 
Equivalence for 1e 
outcome 
(89) 
Stocks et al, 
2010* 
60mg/kg 
Prolastin-C 
weekly 
60mg/kg 
Prolastin 
weekly 
Plasma AAT 
level  
24 10 weeks Equivalence for 1e 
outcome 
(90) 
Campos et al, 
2013* 
120mg/kg 
Prolastin-C 
weekly 
60mg/kg 
Prolastin 
weekly 
Plasma AAT 
level, safety 
30 8 weeks Equivalence for 1e 
outcome, ns diff in 
adverse events 
(91) 
Sandhaus et 
al, 2014* 
60mg/kg 
Glassia 
weekly 
60mg/kg 
Prolastin 
weekly 
Plasma AAT 
level 
50 ≥12 
weeks 
Equivalence for 1e 
outcome, ns diff FEV1 or 
FVC 
(92) 
Observational 
with control 
 
 
 
 
Seersholm et 
al, 1997 
60mg/kg 
Prolastin or 
Trypsone 
weekly 
No 
augmentation 
FEV1 decline 295 1 year Reduced FEV1 decline 53 
v 75ml/year (p=0.02) 
(93) 
AAT registry 
group, 1998 
60mg/kg 
Prolastin 
↓frequency 
or no 
FEV1 decline, 
survival 
1129 12-86 
months 
Better survival (p=0.001), 
ns diff FEV1 decline 
(8) 
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Observational 
with control 
weekly augmentation overall (p=0.40), if FEV1 
35-49%, decline lower on 
Rx (73 v 93 ml/yr, 
p=0.01) 
Wencker et 
al, 2001 
60mg/kg 
augmentation 
weekly 
Data prior to 
augmentation 
FEV1 decline 96 ≥12 
months 
Reduced FEV1 decline 34 
v 49 ml/yr (p=0.02) 
(95) 
Stoller et al, 
2003 
Any dosing 
regimen 
augmentation 
Usual care Adverse 
events 
1129 12-86 
months 
83% augmented patients 
had no adverse events; 
rate 0.02 
events/patient/month 
(94) 
Tonelli et al, 
2009 
Any dosing 
regimen 
augmentation 
No 
augmentation 
FEV1 decline 164 Mean 42 
months 
Reduced FEV1 decline 37 
v 46ml/yr (p=0.05) 
(96) 
Barros-Tizon 
et al, 2012 
60mg/kg 
Prolastin or 
Trypsone at 
any interval 
Data prior to 
augmentation 
Exacerbation 
rate 
127 18 
months 
Reduced exac rate 1.2 v 
1/pa (p<0.01),  reduced 
hospitalisation costs 
(97) 
Observational, Wewers et al, 60mg/kg N/A Serum AAT 21 6 months AAT level improved v (82) 
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no control 
 
 
 
 
 
 
 
 
 
 
 
Observational, 
no control   
 
 
 
 
 
1987 augmentation 
weekly 
level, safety baseline, low adverse 
event rate i.e. safe 
Schmidt et al, 
1988 
60mg/kg 
augmentation 
weekly 
Serum AAT 
level 
20 6 months AAT level maintained at 
35% of normal (equivalent 
to PiMZ) 
(98) 
Barker et al, 
1994 
60mg/kg 
Prolastin 
weekly# 
Functional 
status 
14 12-48 
months 
12/14 patients stabilised 
self-reported functional 
status 
(99) 
Miravitlles et 
al, 1994 
60mg/kg 
Prolastin 
weekly$ 
Safety, AAT 
level 
13 Up to 6 
years 
No significant adverse 
events; 10/13 trough AAT 
>50mg/dl 
(101) 
Barker et al, 
1997 
120mg/kg 
Prolastin 
fortnightly 
AAT level, 
safety 
23 20 weeks Trough levels inadequate 
with fortnightly dosing, 
Rx safe 
(100) 
Schwaiblmair 
et al, 1997 
60mg/kg 
Prolastin 
weekly 
FEV1 20 3 years FEV1 decline 36ml/yr (102) 
Wencker et 
al, 1998 
60mg/kg 
Prolastin 
FEV1 decline, 
safety 
443 3.1-82.8 
months 
FEV1 decline 57ml/yr on 
Rx, which was deemed 
(103) 
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Observational, 
no control              
weekly safe 
Campos et al, 
2009 
Any form of 
augmentation 
Compared 
age >60 to 
<60 
1062 1 year Older subjects exhibited 
more indolent disease with 
fewer exacerbations 
(106) 
Campos et al, 
2009 
Any form of 
augmentation 
Exacerbations 922 1 year Mean exacerbations  
2.4/year, 17 days/episode 
(105) 
Vidal et al, 
2010 
60mg/kg 
Trypsone 
weekly 
Safety 23 24 weeks 1/555 infusions had a 
treatment related adverse 
event 
(108) 
Subramanian 
et al, 2012 
60mg/kg 
Prolastin 
weekly 
PET CT  10 12 weeks Ns difference in PET 
signal on Rx 
(107) 
 
*=Crossover study (either wholly, or as follow on for placebo group) #some patients changed to 120-180mg/kg 2-3 weekly $changed to 
240mg/kg 4 weekly 
Rx= treatment; RCT=randomised controlled trial; FEV1=forced epiratory volume in 1 second; CT=computed tomography; AAT=alpha 1 
antitrypsin; 1e=primary; DLco=gas transfer; 
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Table 4. Criteria required for reference centres for rare diseases (From ref. 130) 
o  Appropriate capacity to diagnose, monitor and manage patients with 
evidence of good outcomes when applicable  
o  Sufficient capacity to provide expert advice, diagnosis or confirmation 
of diagnosis, to produce and adhere to good practice guidelines and to 
implement outcome measures and quality control  
o  Demonstration of a multi-disciplinary approach  
o  High level of expertise and experience documented through 
publications, grants or honorary positions, teaching and training 
activities  
o  Strong contribution to research  
o  Involvement in epidemiological surveillance, such as registries  
o  Close links and collaboration with other expert centres at the national 
and international levels and a capacity to network  
o  Close links and collaboration with patient associations where they 
exist  
o Perform education, information, communication activities to empower 
patients 
o  Although an ENCR should fulfil most of the above criteria, the 
comparative relevance of these various criteria will be influenced (in 
part) by the particular disease or group of diseases covered  
 
Footnote: ENCR: European National Centre of Excellence 
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Table 5. Description of access to care for AATD patients in some Eastern and Western European countries. 
 
East European Centers of A1AT A1AT deficient subjects 
Country Populatio
n 
(million) 
* 
National  
Centers 
(number) 
National Centers 
(location) 
Patients Monitored Access to 
Augmentation 
Augmenta
tion 
Treatment 
Reimbursement (status in 
January 2017) 
Bulgaria 7.09  0 0 by university clinics on 
individual basis 
no access 0 not covered by public health 
insurance 
Croatia 4.22 0 0 by university clinics on 
individual basis 
no access 0 not covered by public health 
insurance 
 
Czech R. 10.55 1 Thomayer Hospital 
Prague 
by National Center (63 
PiZZ pts) 
unrestricted 26/18                      
(in sum, 
now) 
100% covered by public 
health insurance 
Hungary 9.81 4 plan to set up 4 by National Centers no access 0 not covered by public health 
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National Centers at 
universities (2016) 
insurance 
Latvia 1.95 1 Centre of TB and Lung 
Disease, Riga East 
University Hospital 
by National Center 
(approximately 20 PiZZ 
pts) 
limited access 1 not covered by public health 
insurance 
Poland 38.59 1 National Institute of 
Tuberculosis and Lung 
Diseases in Warsaw, 
The Children´s 
Memorial Health 
Institute in Warsaw 
by National Center (70 
pts) 
no access 0 not covered by public health 
insurance 
Romania 19.34 1 Marius Nasta Institute 
of Pneumology, 
Bucharest 
by National Center (7 
pts) 
no access 0 not covered by public health 
insurance 
Russia 143.44 0 0 by university clinics on 
individual basis 
no access 7 not covered by public health 
insurance 
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Serbia 8.80 0 0 by university clinics on 
individual basis 
(approximately 20 pts) 
no access 0 not covered by public health 
insurance 
Slovakia 5.43 3 plan to set up of centers 
(Kosice, Bratislava, 
Vysne Hagy) 
by National Centers limited access 1 every single patient has to 
be individually agreed with 
health insurance  
Slovenia 2.09 0 0 NA no access 0 not covered by public health 
insurance 
 
West European Centers of A1AT A1AT deficient subjects 
Country Populatio
n 
(million) 
* 
National  
Centers 
(number) 
National Centers 
(location) 
Patients Monitored Access to 
Augmentation 
Augmenta
tion 
Treatment 
Reimbursement (status in 
January 2017) 
Austria 8.49  8 Wien, Salzburg, Graz,  
Hörgas-Enzenbach, 
Wels-Grieskirchen, 
by general practitioners unrestricted 130  100% covered by public 
health insurance 
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Natters, Klagenfurt, 
Hohenems 
Belgium 11.48 NA All over the country university hospitals and 
local hospitals by 
pneumologists 
unrestricted 56  100% covered by public 
health insurance, but only 
for patients who started 
therapy before 2010. No 
reimbursement for new 
patients after 2010 
Denmark 5.70 1 Copenhagen by university clinic 
follows up patients on 
individual basis 
no access 0 not covered by public health 
insurance 
France 64.73 NA All over the country by university hospitals, 
local hospitals, private 
practices  
unrestricted (to 
PI SZ and 
PiZZ) 
> 300 100% covered by public 
insurance 
Germany 80.68 60 All over the country by university hospitals, 
local hospitals, private 
practices 
unrestricted >1000 100% covered by health 
insurance 
Italy 59.80 >20 All over the country university hospitals and 
local hospitals by 
pneumologists 
unrestricted  115 100% covered by public 
health insurance 
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Ireland 4.72 1 Dublin by National Center  limited access  23 not covered by public health 
insurance 
Netherla
nds 
15.1 1 Leiden Univ Med 
Center 
by National Center no access 0 not covered by public health 
insurence 
Portugal 10.29 27 All over the country by university hospitals 
and local hospitals by 
pneumologists 
unrestricted 118 100% covered by public 
health insurance 
Spain 46.05 >40 All over the country by university hospitals 
and local hospitals by 
pneumologists 
unrestricted 170 100% covered by public 
health insurance 
UK 65.20 5 Birmingham, 
Edinburgh, Cambridge, 
Coventry, London 
major centres by experts 
and local hospitals by 
pneumologists 
no access but 
some named 
patients with 
panniculitis 
(off label 
indication) 
0  full if approved for  
Individual Funding Request 
(IFR) by local 
commissioners (in NHS 
England) 
*SOURCE: http://www.worldometers.info/ 
NA  non-available data, PTS - patients 
Data provided by: AUSTRIA - Karin Schmid-Scherzer; BELGIUM – Jacques Hutsebaut ; BULGARIA - Kosta Kostov; CROATIA -  Neven 
Tudoric; CZECH R. - Jan Chlumsky; DENMARK -  Asger Dirksen; FRANCE - Gabriel Thabut; GERMANY - Claus Vogelmeier; HUNGARY 
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– Attila Somfay; IRELAND – Noel G. McElvaney; ITALY - Ilaria Ferrarotti; LATVIA - Alvils Krams; NETHERLANDS - Jan Stolk; 
POLAND - Joanna Chorostowska-Wynimko; PORTUGAL - Maria Sucena; ROMANIA - Ruxandra Ulmeanu; RUSSIA - Kirill Zykov; SERBIA 
- Branislava Milenkovic; SLOVAKIA - Ivan Solovic;  SPAIN - Marc Miravitlles; UK – Robert A. Stockley  
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FIGURES 
 
Figure 1. Algorithm for laboratory testing of AATD.  
Footnote: This algorithm describes the current practice of how members of the task 
force treat patients with AATD and is not provided as a general recommendation. 
AAT: alpha-1 antitrypsin; CRP: C reactive protein 
 
 
Figure 2. Algorithm for familial testing for AATD 
Footnote: This algorithm describes the current practice of how members of the task 
force treat patients with AATD and their first degree relatives and is not provided as a 
general recommendation. Wider family testing may be indicated in some instances 
(see text) 
 
 
 
Figure 3. Proposal of a services provision by a reference center in AATD 
Footnote: This algorithm describes the current practice of how members of the task 
force treat patients with AATD and is not provided as a general recommendation 
CXR: Chest X-ray; CT: Computed tomography; MDT: multidisciplinary team 
